Literature DB >> 11259498

The human delta opioid receptor activates G(i1)alpha more efficiently than G(o1)alpha.

H E Moon1, A Cavalli, D S Bahia, M Hoffmann, D Massotte, G Milligan.   

Abstract

To assess the relative capacity of the human delta opioid receptor to activate closely related G proteins, fusion proteins were constructed in which the alpha-subunits of either G(i1) or G(o1), containing point mutations to render them insensitive to the actions of pertussis toxin, were linked in-frame with the C-terminus of the receptor. Following transient and stable expression in HEK 293 cells, both constructs bound the antagonist [(3)H]naltrindole with high affinity. D-ala(2),D-leu(5) Enkephalin effectively inhibited forskolin-stimulated adenylyl cyclase activity in intact cells in a concentration-dependent, but pertussis toxin-insensitive, manner. The high-affinity GTPase activity of both constructs was also stimulated by D-ala(2),D-leu(5) enkephalin with similar potency. However, enzyme kinetic analysis of agonist stimulation of GTPase activity demonstrated that the GTP turnover number produced in response to D-ala(2),D-leu(5) enkephalin was more than three times greater for G(i1)alpha than for G(o1)alpha. As the effect of agonist in both cases was to increase V:(max) without increasing the observed K:(m) for GTP, this is consistent with receptor promoting greater guanine nucleotide exchange, and thus activation, of G(i1)alpha compared with G(o1)alpha. An equivalent fusion protein between the human mu opioid receptor-1 and G(i1)alpha produced a similar D-ala(2),D-leu(5) enkephalin-induced GTP turnover number as the delta opioid receptor-G(i1)alpha fusion construct, consistent with agonist occupation of these two opioid receptor subtypes being equally efficiently coupled to activation of G(i1)alpha.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259498     DOI: 10.1046/j.1471-4159.2001.00196.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

Review 1.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

2.  Regulation of the avidity of ternary complexes containing the human 5-HT(1A) receptor by mutation of a receptor contact site on the interacting G protein alpha subunit.

Authors:  Philip J Welsby; I Craig Carr; Graeme Wilkinson; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

3.  Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.

Authors:  Jeffery N Talbot; David L Roman; Mary J Clark; Rebecca A Roof; John J G Tesmer; Richard R Neubig; John R Traynor
Journal:  J Neurochem       Date:  2009-11-30       Impact factor: 5.372

4.  High- and low-affinity sites for sodium in δ-OR-Gi1α (Cys (351)-Ile (351)) fusion protein stably expressed in HEK293 cells; functional significance and correlation with biophysical state of plasma membrane.

Authors:  Miroslava Vošahlíková; Piotr Jurkiewicz; Lenka Roubalová; Martin Hof; Petr Svoboda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-01       Impact factor: 3.000

5.  Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases.

Authors:  H Kenneth Kramer; Irma Onoprishvili; Matthew L Andria; Kayane Hanna; Karina Sheinkman; Lisa B Haddad; Eric J Simon
Journal:  BMC Pharmacol       Date:  2002-03-01

6.  Mice Expressing Regulators of G protein Signaling-insensitive Gαo Define Roles of μ Opioid Receptor Gαo and Gαi Subunit Coupling in Inhibition of Presynaptic GABA Release.

Authors:  Courtney A Bouchet; Kylie B McPherson; Ming-Hua Li; John R Traynor; Susan L Ingram
Journal:  Mol Pharmacol       Date:  2021-06-16       Impact factor: 4.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.